Detection of epidermal growth factor receptor mutation in non-small-cell lung carcinoma using cytological and histological specimens

Journal of B.U.ON.

Volumn 20, Issue 1, 2015, Pages 142-145

  Xu, Haimiao ^a   Sun, Wenyong ^a   Gu, Zhang ^a   Yue, Cheng ^a  

^a ZHEJIANG CANCER HOSPITAL   (China)

Author keywords

Cytology; EGFR; Histology; Lung carcinomas; Non small cell lung carcinomas

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EGFR PROTEIN, HUMAN; PARAFFIN; TUMOR MARKER;

ADULT; ARTICLE; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; GENE MUTATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOLECULAR PATHOLOGY; NON SMALL CELL LUNG CANCER; PLEURA EFFUSION; PLEURA FLUID; POLYMERASE CHAIN REACTION; THORACOTOMY; CANCER STAGING; COMPARATIVE STUDY; ENZYMOLOGY; EXON; GENETICS; LABORATORY DIAGNOSIS; LUNG TUMOR; MALIGNANT PLEURA EFFUSION; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; TISSUE FIXATION;

ADULT; BIOPSY, FINE-NEEDLE; CARCINOMA, NON-SMALL-CELL LUNG; DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PARAFFIN EMBEDDING; PLEURAL EFFUSION, MALIGNANT; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SPECIMEN HANDLING; TISSUE FIXATION; TUMOR MARKERS, BIOLOGICAL;

EID: 84928705902     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362:2380-2388.
2. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non- small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-128.
3. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
4. Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standard chemotherapy as first-line treatment for Eu ropean patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-246.
5. Rossi G, Graziano P, Leone A, Migaldi M, Califano R. The role of molecular analyses in the diagnosis and treatment of non-small-cell lung carcinomas. Semin Diagn Pathol 2013;30:298-312.
6. Li RC, Zheng LJ, Fang MH, Yu SY. The presence of EGFR mutations predicts the response in Chinese non- small cell lung cancer patients treated with erlotinib. Int J Biol Markers 2014. [Epub ahead of print].
7. Fukihara J, Watanabe N, Taniguchi H et al. Clinical Predictors of Response to EGFR Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Non-Small Cell Lung Cancer. Oncology 2014;86:86-93.
8. Zhou C, Wu YL, Chen G et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735-742.
9. Ying Geng Z, Chang Jiao S, Cui Lin S et al. Third- line therapy in advanced non-small cell lung cancer. JBUON 2013;18:899-907.
10. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
11. Douillard JY, Ostoros G, Cobo M et al. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: A phase-IV, open-label, single-arm study. Br J Cancer 2014;110:55-62.
12. Lai SW, Ho CL, Dai MS et al. Gefitinib as first-line treatment for patients with epidermal growth factor receptor- mutated advanced lung adenocarcinoma: A single institution experience in Taiwan. JBUON 2014;19:459-465.
13. Kohler J, Schuler M. Afatinib, erlotinib and gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: A review. Onkologie 2013;36:510- 518.
14. Gridelli C, de Marinis F, Cappuzzo F et al. Treatment of Advanced Non-Small-Cell Lung Cancer with Epidermal Growth Factor Receptor (EGFR) Mutation or ALK Gene Rearrangement: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. Clin Lung Cancer 2013;S1525- 7304:00259-3.
15. Jang SH. Long Term Therapeutic Plan for Patients with Non-Small Cell Lung Cancer Harboring EGFR Mutation. Tuberc Respir Dis (Seoul) 2014;76:8-14.
16. Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500.
17. Travis WD, Brambilla E, Noguchi M et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung ade nocarcinoma. J Thorac Oncol 2011;6:244-285.
18. Aisner DL, Deshpande C, Baloch Z et al. Evaluation of EGFR mutation status in cytology specimens: An in stitutional experience. Diagn Cytopathol 2013;41:316- 323.
19. Han HS, Eom DW, Kim JH et al. EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases. Clin Lung Cancer 2011;12:380-386.
20. Ellison G, Donald E, McWalter G et al. A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples. J Exp Clin Cancer Res 2010;29:132.
21. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.